Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis.
Gadolinium-enhancing lesions in the brain are commonly used as a primary outcome measure of disease activity in phase I/II clinical trials in multiple sclerosis (MS). The advent of effective therapy and the cost of clinical trials have led some researchers to adopt a one-arm study design with selection towards patients showing MRI activity. Regression to the mean is recognized as an important consideration in these trials, but the additional confounding effect of alternating active and inactive phases of disease has not been considered. Simulated data were generated from Poisson and normal distributions to mimic outcomes from phase I/II clinical trials of patients with relapsing-remitting MS under a constant or changing disease process model. In all cases, conventional comparison of pretreatment to on-treatment measurements overestimated the treatment effect. Although correction for regression to the mean provided unbiased estimates of the treatment effect under a constant disease process model, this correction also overestimated the treatment effect when disease activity changed over time. Conversely, unbiased estimates of the treatment effect under an alternating (active/inactive) disease process were obtained by correctly accounting for regression to the mean and the disease process. The implications of these results are discussed in terms of efficacy and safety.
Healy
Brian C
BC
Department of Neurology, Brigham and Women's Hospital, Partners MS Center, Harvard Medical School, Boston, MA 02115, USA.
Hayden
Douglas L
DL
Sampat
Mehul P
MP
Bakshi
Rohit
R
Guttmann
Charles R G
CR
D001921:Brain / Q000503:physiopathology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003198:Computer Simulation; D005682:Gadolinium / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D015233:Models, Statistical; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000503:physiopathology* / Q000628:therapy*; D016011:Normal Distribution; D016012:Poisson Distribution; D016896:Treatment Outcome
D005682:Gadolinium